<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04385550</url>
  </required_header>
  <id_info>
    <org_study_id>ALTN-AK05-III-01</org_study_id>
    <nct_id>NCT04385550</nct_id>
  </id_info>
  <brief_title>A Study of Anlotinib Hydrochloride Capsule Combined With AK105 Injection in Subject With Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma</brief_title>
  <official_title>A Randomized, Open-label, Controlled, Multicenter Phase III Study of Hydrochloride Capsule Combined With AK105 Injection Versus Standard Second-line Chemotherapy for Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, controlled, open-label, multicenter study to evaluate efficacy of AK105
      injection combined with Anlotinib Hydrochloride Capsules versus standard second-line
      chemotherapy. Patients are treated with AK105 injection combined with Anlotinib Hydrochloride
      Capsules or standard second-line chemotherapy, with 1:1 random ratio.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 20, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 45 weeks</time_frame>
    <description>OS defined as the time from randomization to death from any cause. Subjects who do not die at the end of the extended follow-up period, or were lost to follow-up during the study, were censored at the last date they were known to be alive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 45 weeks</time_frame>
    <description>PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>up to 45 weeks</time_frame>
    <description>Percentage of subjects achieving complete response (CR) and partial response (PR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>up to 45 weeks</time_frame>
    <description>Percentage of subjects achieving complete response (CR) and partial response (PR) and stable disease (SD).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>up to 45 weeks</time_frame>
    <description>DOR defined as time from earliest date of disease response to earliest date of disease progression based on radiographic assessment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">528</enrollment>
  <condition>Advanced Gastric and Gastro-oesophageal Junction Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Anlotinib hydrochloride capsule + AK105 injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21) plus AK105 200mg intravenously (IV) on Day 1 of each 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Second-line Chemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive 80 mg/m² IV paclitaxel on Days 1, 8 and 15 of each 28-day cycle, or 75mg/m² docetaxel every 3 weeks of each 21-day cycle until disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib hydrochloride capsule</intervention_name>
    <description>Anlotinib hydrochloride capsule 12mg given orally in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21).</description>
    <arm_group_label>Anlotinib hydrochloride capsule + AK105 injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AK105 injection</intervention_name>
    <description>AK105 200mg intravenously (IV) on Day 1 of each 21-day cycle.</description>
    <arm_group_label>Anlotinib hydrochloride capsule + AK105 injection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel injection</intervention_name>
    <description>Paclitaxel injection 80mg / m² IV on Days 1, 8 and 15 of each 28-day cycle.</description>
    <arm_group_label>Standard Second-line Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel injection</intervention_name>
    <description>Docetaxel injection 75mg / m² IV every 3 weeks of each 21-day cycle.</description>
    <arm_group_label>Standard Second-line Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Understood and signed an informed consent form; 2.Eastern Cooperative Oncology
             Group (ECOG) performance status score of 0 or 1; Life expectancy ≥ 3 months; 3.
             Histopathology or cytology confirmed as metastatic or local advanced gastric and
             gastro-oesophageal junction adenocarcinoma; 4. First-line standard chemotherapy
             regimen in patients with advanced gastric or gastroesophageal junction adenocarcinoma
             after treatment failure; 5. Has at least one measurable lesion; 6. Weight ≥40 kg or
             BMI ≥18.5; 7. Adequate organ function; 8. Male or female subjects should agree to use
             an adequate method of contraception starting with the first dose of study therapy
             through 6 months after the last dose of study (such as intrauterine devices ,
             contraceptives or condoms) ;No pregnant or breastfeeding women, and a negative
             pregnancy test are received within 7 days before the randomization.

        Exclusion Criteria:

          -  1. Histopathology confirmed as squamous cell carcinoma, carcinoid, undifferentiated
             carcinoma, or other gastric cancer; 2. HER2 positive; 3. Has received paclitaxel or
             docetaxel in the first-line treatment; 4. Has received paclitaxel or docetaxel in the
             neoadjuvant or adjuvant treatment regimen and have relapsed or metastasized within 6
             months after the last dose; 5. Has other malignant tumors within 5 years; 6. Has used
             anti-angiogenic drugs such as anlotinib, apatinib, lenvatinib, sorafenib, sunitinib,
             bevacizumab, or related immunotherapy drugs for PD-1, PD-L1, etc; 7. Severe
             hypersensitivity after administration of other monoclonal antibodies; 8. Has spinal
             cord compression, cancerous meningitis and symptomatic brain metastasis； 9. Has
             adverse events caused by previous therapy except alopecia that did not recover to
             ≤grade 1; 10. Has received radiotherapy, chemotherapy and surgery within 4 weeks
             before the first dose; 11. Has gastrointestinal bleeding tendency within 4 weeks
             before the first dose; 12. The tumor has invaded important blood vessels and will
             cause fatal bleeding; 13. Has multiple factors affecting oral medication; 14. Has
             uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated
             drainage; 15. Has any active autoimmune disease or history of autoimmune disease; 16.
             Immunosuppressant or systemic or absorbable local hormone therapy is required to
             achieve the aim of immunosuppression (dose &amp;gt; 10mg/ day prednisone or other
             therapeutic hormones) and is still used within 2 weeks after the first administration;
             17. Has any serious and / or uncontrolled disease; 18. Has active viral infection; 19.
             Has participated in other anticancer drug clinical trials within 4 weeks; 20.
             According to the judgement of the investigators, there are other factors that may lead
             to the termination of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ruihua Xu</last_name>
    <phone>020-87343468</phone>
    <email>ruihxu@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Anhui Medical University</name>
      <address>
        <city>Hefei</city>
        <state>Anhui</state>
        <zip>230022</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Kangsheng Gu, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Kangsheng Gu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Shijitan Hospital Affiliated to Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100038</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jirun Peng, Doctor</last_name>
      <email>1446316766@qq.com</email>
    </contact>
    <investigator>
      <last_name>Jirun Peng, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Sixth Medical Center of PLA General Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100048</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xinhong Zhang, Doctor</last_name>
      <email>zhangxh1970@sina.com</email>
    </contact>
    <investigator>
      <last_name>Xinhong Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Peking University Shougang Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100144</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Delin Wang</last_name>
      <email>dlwang163@sohu.com</email>
    </contact>
    <investigator>
      <last_name>Delin Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Luhe Hospital Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>101100</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Dong Yan, Doctor</last_name>
      <email>yd15yt88@163.com</email>
    </contact>
    <investigator>
      <last_name>Dong Yan, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beijing Tsinghua Changgung Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>102218</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhuo Yu, Doctor</last_name>
      <email>yuzhuo@vip.sina.com</email>
    </contact>
    <investigator>
      <last_name>Zhuo Yu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fujian Provincial Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350011</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zengqing Guo</last_name>
    </contact>
    <investigator>
      <last_name>Zengqing Guo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Quanzhou First Hospital</name>
      <address>
        <city>Quanzhou</city>
        <state>Fujian</state>
        <zip>362000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Peiling Xin</last_name>
      <email>xinpeiling62@126.com</email>
    </contact>
    <investigator>
      <last_name>Peiling Xin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Quanzhou</city>
        <state>Fujian</state>
        <zip>362000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Tianwen Xu, Doctor</last_name>
      <email>xutianwen53@163.com</email>
    </contact>
    <investigator>
      <last_name>Tianwen Xu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361003</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jiayi Li</last_name>
      <email>ljy778848@qq.com</email>
    </contact>
    <investigator>
      <last_name>Jiayi Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361004</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhijie Ding, Doctor</last_name>
      <email>zhijieding@sina.com</email>
    </contact>
    <investigator>
      <last_name>Zhijie Ding, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Lanzhou University</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiaoming Hou, Doctor</last_name>
      <email>1795950416@qq.com</email>
    </contact>
    <investigator>
      <last_name>Xiaoming Hou, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gansu Wuwei Tumour Hospital</name>
      <address>
        <city>Wuwei</city>
        <state>Gansu</state>
        <zip>733000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Linzhi Lu</last_name>
      <email>lulinzh12006@163.com</email>
    </contact>
    <investigator>
      <last_name>Linzhi Lu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Ruihua Xu, Doctor</last_name>
      <email>ruihxu@163.com</email>
    </contact>
    <investigator>
      <last_name>Ruihua Xu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Sixth Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510610</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yanhong Deng, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Yanhong Deng, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Guangdong Medical University</name>
      <address>
        <city>Zhanjiang</city>
        <state>Guangdong</state>
        <zip>524000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhong Xie</last_name>
      <email>xiexieg@126.com</email>
    </contact>
    <investigator>
      <last_name>Zhong Xie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guangxi Medical University Affiliated Tumor Hospital</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi Zhuang Autonomous Region</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jiansi Chen</last_name>
      <email>wcwk0771@126.com</email>
    </contact>
    <investigator>
      <last_name>Jiansi Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fourth Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050010</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Da Jiang</last_name>
      <email>jiangda139@163.com</email>
    </contact>
    <investigator>
      <last_name>Da Jiang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbin Medical University Cancer Hospital</name>
      <address>
        <city>Harbin</city>
        <state>Heilongjiang</state>
        <zip>150040</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yanqiao Zhang, Doctor</last_name>
      <email>yanqiaozhang@126.com</email>
    </contact>
    <investigator>
      <last_name>Yanqiao Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AnYang Tumor Hospital</name>
      <address>
        <city>Anyang</city>
        <state>Henan</state>
        <zip>455000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Tao Wu</last_name>
      <email>wuren909@163.com</email>
    </contact>
    <investigator>
      <last_name>Tao Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xinxiang Central Hospital</name>
      <address>
        <city>Xinxiang</city>
        <state>Henan</state>
        <zip>453000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Guifang Zhang</last_name>
      <email>xxchzhangguifang@126.com</email>
    </contact>
    <investigator>
      <last_name>Guifang Zhang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhengzhou University</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450003</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yanru Qin, Doctor</last_name>
      <email>yanruqin@163.com</email>
    </contact>
    <investigator>
      <last_name>Yanru Qin, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Huijuan Wu</last_name>
    </contact>
    <investigator>
      <last_name>Huijuan Wu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Union Hospital,Tongji Medical College,Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Tao Zhang, Doctor</last_name>
      <email>1277577866@qq.com</email>
    </contact>
    <investigator>
      <last_name>Tao Zhang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College, Huazhong University of Science &amp; Technology</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xianglin Yuan, Doctor</last_name>
      <email>xlyuan1020@163.com</email>
    </contact>
    <investigator>
      <last_name>Xianglin Yuan, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hubei Cancer Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430079</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xinjun Liang, Doctor</last_name>
      <email>doctorlxj@163.com</email>
    </contact>
    <investigator>
      <last_name>Xinjun Liang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410008</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shan Zeng, Doctor</last_name>
      <email>Shanzeng2012@163.com</email>
    </contact>
    <investigator>
      <last_name>Shan Zeng, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410011</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Hongliang Yao, Doctor</last_name>
      <email>yaohl0326@163.com</email>
    </contact>
    <investigator>
      <last_name>Hongliang Yao, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shanzhi Gu</last_name>
      <email>105575191@qq.com</email>
    </contact>
    <investigator>
      <last_name>Shanzhi Gu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210009</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianwei Lu, Doctor</last_name>
      <email>lujw@medmail.com.cn</email>
    </contact>
    <investigator>
      <last_name>Jianwei Lu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Lingjun Zhu, Doctor</last_name>
    </contact>
    <investigator>
      <last_name>Lingjun Zhu, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nantong Cancer Hospital</name>
      <address>
        <city>Nantong</city>
        <state>Jiangsu</state>
        <zip>226361</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jianhong Wang</last_name>
      <email>ywk_wjh@163.com</email>
    </contact>
    <investigator>
      <last_name>Jianhong Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wuxi People's Hospital</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214023</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Chaoying Liu</last_name>
      <email>chyliu666@163.com</email>
    </contact>
    <investigator>
      <last_name>Chaoying Liu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital of Jiangnan University</name>
      <address>
        <city>Wuxi</city>
        <state>Jiangsu</state>
        <zip>214062</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yong Mao, Doctor</last_name>
      <email>mydoctorwx@aliyun.com</email>
    </contact>
    <investigator>
      <last_name>Yong Mao, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <state>Jiangxi</state>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Junhe Li, Doctor</last_name>
      <email>mailto:lijunhe88@163.com</email>
    </contact>
    <investigator>
      <last_name>Junhe Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Liaoning Cancar Hospital</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <zip>110042</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Baoli Qin, Doctor</last_name>
      <email>poryqin@126.com</email>
    </contact>
    <investigator>
      <last_name>Baoli Qin, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Ningxia Hui Autonomous Region</name>
      <address>
        <city>Yinchuan</city>
        <state>Ningxia Hui Autonomous Region</state>
        <zip>750021</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qingxin Zhuang</last_name>
      <email>zhuangtse@163.com</email>
    </contact>
    <investigator>
      <last_name>Qingxin Zhuang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shandong Cancer Hospital</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>250117</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Changzheng Li</last_name>
      <email>liczdoc@163.com</email>
    </contact>
    <investigator>
      <last_name>Changzheng Li</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanghai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200080</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Qi Li, Doctor</last_name>
      <email>leeqi2001@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Qi Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shanxi Provincial Cancer Hospital</name>
      <address>
        <city>Taiyuan</city>
        <state>Shanxi</state>
        <zip>030013</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yusheng Wang, Doctor</last_name>
      <email>wangyusheng1972@163.com</email>
    </contact>
    <investigator>
      <last_name>Yusheng Wang, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710004</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xi Chen, Doctor</last_name>
      <email>2002chenxi@163.com</email>
    </contact>
    <investigator>
      <last_name>Xi Chen, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>First Affiliated Hospital of Xi'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710061</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Enxiao Li, Doctor</last_name>
      <email>doclienxiao@sina.com</email>
    </contact>
    <investigator>
      <last_name>Enxiao Li, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjing</city>
        <state>Tianjing</state>
        <zip>300050</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Diansheng Zhong, Doctor</last_name>
      <email>zhongdsh@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Diansheng Zhong, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Institute and Hospital</name>
      <address>
        <city>Tianjing</city>
        <state>Tianjing</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yi Ba, Doctor</last_name>
      <email>yiba99@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Yi Ba, Doctor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of kashi region</name>
      <address>
        <city>Kashi</city>
        <state>XinJiang Uighur Autonomous Region</state>
        <zip>844000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wei Wang</last_name>
      <email>271865348@qq.com</email>
    </contact>
    <investigator>
      <last_name>Wei Wang</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 9, 2020</study_first_submitted>
  <study_first_submitted_qc>May 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2020</study_first_posted>
  <last_update_submitted>May 9, 2020</last_update_submitted>
  <last_update_submitted_qc>May 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

